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Fungal infections are common and diverse in South Africa (SA), 
driven in large part by the syndemics of HIV, tuberculosis (TB) and 
poverty. SA has the dubious distinctions of having the largest HIV 
epidemic,[1] one of the highest incidences of TB,[2] and – by some 
measures – the most socioeconomic inequity[3] in the world. Each 
of these conditions on its own or in combination can predispose 
individuals to fungal disease, but to our knowledge, the burden of 
such infections in SA has not previously been estimated.
Objectives
To estimate the prevalence and incidence of fungal infections in SA, 
excluding cutaneous infections with the sole exception of tinea capitis 
because of its severity in a significant minority of children.
Methods
The burden of fungal disease in SA was estimated using the 
methodologies of LIFE-worldwide.org.[4] Starting estimates for fungal 
disease or for conditions complicated by fungal disease were obtained 
by review of the English language literature. National or local 
data were preferred, but where these were unavailable, data were 
extrapolated from other sources in order of decreasing preference: 
from other countries in southern Africa, elsewhere in Africa, non-
African middle-income countries, and non-African non-middle-
income countries. We also calculated 25% sensitivity bounds (25% 
lower and 25% higher than the base estimate) to reflect uncertainty 
in these estimates.
Prevalence data for conditions that may become complicated by 
fungal infections were obtained from national surveys, registries or 
published estimates (Table 1). SA population estimates and HIV-
related deaths were obtained from Statistics South Africa.[5] The 
number of people living with HIV/AIDS (PLWH), the proportion 
of adult (≥15 years) PLWH with CD4+ counts <200 cells/µL, and 
antiretroviral therapy (ART) coverage were obtained from the 
Thembisa model, version 3.2.[6] Among adult PLWH with CD4+ 
counts <200 cells/µL, we assumed that half had counts <100 cells/
µL based on Carmona et al.,[7] who reported that of 654 868 PLWH 
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Background. With a population of 56.5 million, over 7 million persons living with HIV, one of the world’s highest rates of tuberculosis (TB) 
and a large proportion of the population living in poverty, South Africa (SA)’s fungal disease burden is probably substantial and broad in scope.
Objectives. To estimate the burden of fungal disease in SA.
Methods. Using total and at-risk populations and national, regional and occasionally global data, we estimated the incidence and prevalence 
of the majority of fungal diseases in SA.
Results. Estimates for the annual incidence of HIV-related life-threatening fungal disease include cryptococcal meningitis (8 357 cases), 
Pneumocystis pneumonia (4 452 cases) and endemic mycoses (emergomycosis, histoplasmosis and blastomycosis, with 100, 60 and 10 cases 
per year, respectively). We estimate 3 885 cases of invasive aspergillosis annually. The annual burden of candidaemia and Candida peritonitis 
is estimated at 5 421 and 1 901 cases, respectively. The epidemic of pulmonary TB has probably driven up the prevalence of chronic 
pulmonary aspergillosis to 99 351 (175.8/100 000), perhaps the highest in the world. Fungal asthma probably affects >100 000 adults. 
Mucosal candidiasis is common, with an annual prevalence estimated at 828 666 and 135 289 oral and oesophageal cases, respectively, 
complicating HIV infection alone (estimates in other conditions not made), and over a million women are estimated to be affected by 
recurrent vulvovaginal candidiasis each year. Tinea capitis in children is common and conservatively estimated at >1  000 000 cases. 
The inoculation mycoses sporotrichosis, chromoblastomycosis and eumycetoma occur occasionally (with 40, 40 and 10 cases estimated, 
respectively). Overall, we estimate that over 3.2 million South Africans are afflicted by a fungal disease each year (7.1% of the population).
Conclusions. Significant numbers of South Africans are estimated to be affected each year by fungal infections, driven primarily by the 
syndemics of HIV, TB and poverty. These estimates emphasise the need for better epidemiological data, and for improving the diagnosis 
and management of these diseases.
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who entered care in SA in 2016, 32.9% had CD4+ counts <200 cells/
µL and 16.8% had counts <100 cells/µL, and Coetzee et al.,[8] who 
reported that among PLWH who had a CD4+ measurement in 
2014 - 2015, 20.56% had counts <200 cells/µL and 9.69% had counts 
<100  cells/µL.[8] National TB data were obtained from the World 
Health Organization (WHO).[2] National prevalence data for lung 
cancer and chronic obstructive pulmonary disease (COPD) and 
incidence data for acute myeloid leukemia (AML) were obtained 
from the 2016 Global Burden of Disease study.[9] The prevalence of 
asthma in adults was assumed to be 6.09%, based on the World Health 
Survey. [10] Transplantation volume was obtained from the Organ 
Donor Foundation.[11] The number of autologous stem cell transplants 
in 2014 was obtained from Passweg et al.,[12] and the number of end-
stage kidney disease patients receiving peritoneal dialysis (PD) in 2015 
was reported by the South African Renal Registry.[13]
Assumptions on which we predicated estimates of each mycosis 
are detailed in Table 2. The burden of cryptococcal meningitis 
was obtained using national laboratory surveillance data from the 
National Health Laboratory Service’s Group for Enteric, Respiratory 
and Meningeal Diseases Surveillance in South Africa (GERMS-SA),[14] 
with a correction of 20% to account for the possibility of undiagnosed 
cases. We estimated the burden of Pneumocystis pneumonia (PCP) 
in adults and children separately. For adults, we assumed that 10% 
of PLWH who had CD4+ counts <100 cells/µL were hospitalised 
each year;[15] and based on the observation from SA that ~10% of 
PLWH admitted to hospital with WHO danger signs and cough were 
diagnosed with PCP,[16] we assumed that 5% of hospitalisations among 
PLWH who had CD4+ counts <100 cells/µL were caused by PCP. We 
assumed that 21% of childhood pneumonia deaths were attributable 
to PCP, based on data from Botswana;[17] additionally, we assumed 
that childhood PCP carried a 40% mortality rate.[18,19] Invasive 
aspergillosis (IA) was assumed to occur as a complication of other 
disease states or immunocompromising conditions. IA was assumed 
to complicate 10% of cases of AML, and an equivalent number of 
cases among all other non-AML haematological malignancies.[20] IA 
was assumed to complicate 10% of allogeneic stem cell transplants, 
0.5%, 4%, 6%, and 4% of kidney, lung, heart and liver transplants, 
respectively, based on North American data,[21] and 2.6% of cases of 
lung cancer, based on Chinese data.[22] IA was additionally assumed 
to complicate 1.3% of severe acute exacerbations of COPD requiring 
hospitalisation (which was assumed to affect the most severe decile 
of patients with this condition).[23] Although IA was implicated in 
4% of HIV-related deaths in a study from Italy,[24] similar findings 
have not been reported in autopsy studies from SA.[25-29] We therefore 
conservatively estimated that 0.5% of HIV-related deaths were caused 
by IA. Mucormycosis was assumed to affect 2 per million of the 
population based on data from Europe.[30,31]
Chronic pulmonary aspergillosis (CPA) was assumed to complicate 
pulmonary TB with and without cavitary lesions in 22% and 2% of 
cases, respectively.[32,33] We assumed that 22% of cases of pulmonary 
TB cavitate. We also assumed that pulmonary TB is the underlying 
diagnosis in 80% of all CPA cases. Allergic bronchopulmonary 
aspergillosis (ABPA) was assumed to occur in 2.5% of adult 
asthmatics, based on SA and international data.[34,35] Severe asthma 
with fungal sensitisation (SAFS) was estimated to occur in 30% of the 
most severe decile of asthmatics.[36] Although ABPA is also known to 
complicate cystic fibrosis, estimates of the prevalence of this disease 
in SA were unavailable.
The burden of candidaemia was assumed to occur in intensive 
care unit (ICU) and non-ICU inpatient settings at a ratio of 
2:1. [37] We determined the number of ICU beds from a national 
survey from 2008 to 2009[38] and assumed 90% bed utilisation. The 
Table 1. Population characteristics and underlying comorbidities in South Africans
Population characteristic n Source
Total population 56 521 947 Statistics South Africa[5] 
Women aged 15 - 54 years 16 708 323 Statistics South Africa[5] 
Children (<15 years) 16 724 831 Statistics South Africa[5] 
Persons living with HIV 7 046 301 Thembisa model[6] 
Adults living with HIV + CD4+ <200 cells/µL 676 445 Thembisa model[6] 
Adults livings with HIV + CD4+ <350 cells/µL 2 012 674 Thembisa model[6] 
Persons living with HIV on ART 372 3118 Thembisa model[6] 
Children living with HIV 329 430 Thembisa model[6] 
Children living with HIV on ART 181 372 Thembisa model[6] 
AIDS deaths 126 755 Statistics South Africa[5] 
Annual cases of TB 438 000 World Health Organization[2] 
Annual cases of pulmonary TB 394 000 World Health Organization[2]*
Adults with asthma 2 477 539 World Health Survey[10] 
Adults with COPD 2 249 688 Global Burden of Disease 2015[9] 
Renal transplants per year 249 Organ Donor Foundation[11] 
Lung transplants per year 14 Organ Donor Foundation[11] 
Heart transplants per year 25 Organ Donor Foundation[11] 
Liver transplants per year 35 Organ Donor Foundation[11] 
Allogeneic stem cell transplants per year 107 EBMT survey[12] 
Persons with lung cancer 7 793 Global Burden of Disease 2015[9]
Persons with acute myelogenous leukaemia 518 Global Burden of Disease 2015[9] 
Persons on peritoneal dialysis 1 668 South African Renal Registry[13]
ICU beds 4 719 Naidoo et al., 2013[38] 
ART = antiretroviral therapy; TB = tuberculosis; COPD = chronic obstructive pulmonary disease; EBMT = European Society for Blood and Marrow Transplantation; ICU = intensive care unit.
*Adjusted based on assumption that 90% of TB cases are pulmonary.
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incidence of ICU-associated candidaemia in public hospital ICUs was 
extrapolated from cross-sectional data from Soweto.[39,40] We assumed 
that the rate of candidaemia in private hospital ICUs was half that 
of public hospital ICUs, based on the assumption of lower general 
acuity and complexity of private hospital ICU patients that follows 
from greater accessibility (75% of ICU beds were in the private sector, 
which provides care for ~15% of the population[38]). We assumed that 
post-surgical Candida peritonitis (intra-abdominal candidiasis) was 
Table 2. Assumptions on which estimates of mycoses are predicated*
Mycosis Assumptions
Geographical origin of data 
informing assumptions† Reference
Cryptococcal meningitis Reported surveillance data from NICD, plus 20% 
correction for missed diagnoses
National GERMS-SA 2017[14] 
Pneumocystis pneumonia For adults, assumed to cause 5% of all 
hospitalisations among PLWH with CD4+ 
<100 cells/µL (10% of whom were assumed to  
be hospitalised each year)
In children, PCP assumed to be attributable for 21% 
of childhood pneumonia deaths and we assumed 
that 40% childhood PCP cases were fatal
National + regional Maartens et al., 2018[16]
Meyer-Rath et al., 2013[15]
Ansari et al., 2003[17]
Zar et al., 2001[18]
Morrow et al., 2014[19] 
Invasive aspergillosis Complicates 10% of cases of AML per year and an 
equivalent number among all other haematological 
malignancies; complicates 10% of allogeneic 
HSCT, 0.5% of kidney SOT, 4% of lung SOT, 6% 
of heart SOT, 4% of liver SOT, and 2.6% of cases 
of lung cancer; 0.5% of patients dying of HIV; and 
1.3% of the worst 10% of COPD patients (usually 
hospitalised)
International Lortholary et al., 2011[20]
Herbrecht et al., 2012[21]
Antinori et al., 2009[24]
Karat et al., 2016[25]
Martinson et al., 2007[26]
Wong et al., 2012[27]
Murray et al., 2007[28]
CPA Complicates 22% of pulmonary TB cases with 
cavitation and 2% of pulmonary TB cases without 
cavitation; cavitary disease assumed to comprise 
22% of cases of pulmonary TB. Pulmonary TB 
assumed to underlie 80% of cases of CPA
National + international Denning et al., 2011[32]
Sonnenberg et al., 2000[33] 
ABPA Assumed to affect 2.5% of asthmatic adults National + international Benatar et al., 1980[34]
Denning et al., 2013[35] 
SAFS Assumed to affect 30% of the most severe decile of 
asthmatic adults
International Denning et al., 2014[36] 
Candidaemia Rate of ICU-associated candidaemia in adults in 
public hospital ICUs is assumed to be equivalent to 
that reported at Chris Hani Baragwanath Hospital, 
and assumed to be double that of private hospital 
ICUs. 90% of ICU beds assumed to be occupied.
Ratio of candidaemic episodes in adults receiving 
care in ICU to non-ICU beds assumed to be 2:1
National + international Kreusch and Karstaedt, 
2013[39]
Tshukutsoane and Scribante, 
2008[40]
Govender et al., 2016[37] 
Candida peritonitis Post-surgical Candida peritonitis is half as common 
as ICU-related candidemia; PD patients assumed to 
have 1.7 episodes of peritonitis per year, with 3.8% 
due to Candida
National + international Montravers et al., 2011[41]
Okpechi et al., 2012[42]
Isla et al., 2014[43] 
Oral candidiasis Among adults, 38% of PLWH with CD4+ 
<350 cells/µL; for children living with HIV, oral 
candidiasis assumed to affect 37% not on ART  
and 5% on ART
National + regional Arendorf et al., 1998[44]
Nanteza et al., 2014[45]
Meless et al., 2014[46]
Rwenyonyi et al., 2011[48] 
Oesophageal candidiasis 20% of PLWH with CD4 <200 cells/µL International Smith and Orholm, 1990[49] 
Recurrent vulvovaginal 
candidiasis
~6% of women between 15 and 54 years of age International Foxman et al., 2013[53]
Denning et al., 2018[79] 
Tinea capitis 6% of children <15 years of age National + regional Nweze and Eke, 2017[54]
Young, 1976[55]
Mucormycosis 2 cases per million population International Bitar et al., 2009[31]
NICD = National Institute of Communicable Diseases; GERMS-SA = National Health Laboratory Service Group for Enteric, Respiratory and Meningeal Diseases Surveillance in South Africa; 
PLWH = persons living with HIV; PCP = Pneumocystis pneumonia; AML = acute myelogenous leukaemia; HSCT = haematopoietic stem cell transplantation; SOT = solid organ transplantation; 
COPD = chronic obstructive pulmonary disease; TB = tuberculosis; CPA = chronic pulmonary aspergillosis; ABPA = allergic bronchopulmonary aspergillosis; SAFS = severe asthma with fungal 
sensitisation; ICU = intensive care unit; PD = peritoneal dialysis; ART = antiretroviral therapy.
*Estimates for emergomycosis, histoplasmosis, sporotrichosis, blastomycosis, chromoblastomycosis and eumycetoma were based on literature review and the authors’ unpublished observations.
†Regional implies another country in sub-Saharan Africa, while international implies outside sub-Saharan Africa.
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half as frequent as ICU-associated candidaemia, as it was in France.[41] 
In addition, the incidence of Candida peritonitis associated with PD 
was estimated based on the number of PD patients and according to 
reports of PD-associated peritonitis from Cape Town and Limpopo 
Province.[42,43] Oral candidiasis was assumed to affect 38% of adult 
PLWH who had CD4+ counts <350 cells/µL; this estimate was 
based on a large SA study in the pre-ART era that reported oral 
candidiasis among 38% of HIV-infected patients,[44] in addition to a 
study from Uganda that suggested that this opportunistic infection 
is significantly more likely below this CD4+ threshold.[45] Oral 
candidiasis was assumed to affect 5% of children living with HIV 
on ART[46] and 37% of children living with HIV not taking ART,[47,48] 
based on data from elsewhere in sub-Saharan Africa. Oesophageal 
candidiasis was assumed to affect 20% of adult PLWH who had CD4+ 
counts <200 cells/µL, based on a study from Denmark of patients 
with AIDS;[49] estimates were not attempted for this disease among 
children. Although vulvovaginal candidiasis occurs more frequently 
in HIV-infected women than in HIV-uninfected women,[50] most SA 
studies are cross-sectional and not longitudinal, and therefore do 
not inform the incidence of recurrence.[50,51] Based on international 
data,[52,53] we conservatively assumed that recurrent vulvovaginal 
candidiasis – defined as ≥4 episodes per year – had a prevalence of 
6% among females aged 15 - 54 years; this risk was not adjusted for 
HIV status.
Based on a review of SA and southern African literature, we 
estimated the prevalence of tinea capitis among children aged 
<15  years to be 6%.[54,55] Among these, at least 2% and perhaps as 
many as 14% of cases are complicated, with inflammatory tinea 
capitis or kerion.[56,57] The incidences of endemic and inoculation 
mycoses were estimated based on the authors’ experience and the 
published literature.[58-63] We could find no data on fungal keratitis.
Results
In total, we estimated the occurrence of 3  220 014 cases of fungal 
infections each year (Table 3), with a sensitivity bounds of 2 415 010 - 
4 025 017. We estimated 8 357 cases of HIV-associated cryptococcal 
meningitis each year (14.8/100 000). This disease is rare in children: 
3% of cases audited by GERMS-SA were diagnosed in patients aged 
<15 years.[14] We estimated 1 691 cases of PCP per year in adults 
(4.3/100 000) and 2 761 cases in children (16.5/100 000), for a total of 
4 452 cases per year (7.9/100 000).
We estimated a total of 3 885 cases of IA annually (4.7/100 000), 
including 3 128 cases among persons with COPD or lung cancers, 
576 cases among PLWH and 120 cases among persons with other 
malignancies or transplant recipients. There were estimated to be 
394 000 cases of pulmonary TB per year;[2] it was assumed that 
10% of these patients died, leaving an estimated 354 600 survivors. 
We estimated 22 694 incident cases annually and 71 533 prevalent 
cases of CPA complicating TB (carrying an annual 15% mortality 
or surgical resection rate). In total, the prevalent burden of CPA was 
estimated as 89 416 cases. The burdens of ABPA and SAFS were 
estimated as 60 591 and 79 980 cases, respectively, although there 
is likely to be some duplication: some ABPA patients have severe 
asthma, and all are sensitised to Aspergillus fumigatus.
In 2008 - 2009, there were 4 719 critical care beds in SA.[38] Of 
these, 3 533 (75%) were in private sector hospitals that provide care 
for ~15% of the population,[64] and 1 186 (25%) were in the public 
sector.[38] We assumed an occupation rate of 90% of ICU beds across 
both public and private hospitals. Between 2005 and 2007, there were 
49 episodes of candidaemia reported in adult ICU patients at Chris 
Hani Baragwanath Hospital, a 2 700-bed tertiary hospital in Soweto 
with an 18-bed ICU,[39] giving a rate of 1.36 episodes of candidaemia 
per ICU bed per year. If one extrapolates this rate to all occupied 
public hospital ICU beds and assumes that this rate is halved in 
private hospital ICUs, it can be calculated that there were 3 614 
episodes of candidaemia in adult ICUs. Govender et al.[37] noted that 
two-thirds of episodes of candidaemia occurred in ICU patients in a 
passive laboratory-based surveillance programme tracking resistance 
to antifungal drugs in Candida species in SA (TRAC-South Africa). 
We would therefore expect 1 807 episodes in adults outside ICUs 
for a total of 5 421 episodes of candidaemia per year (9.6/100 000). 
Reliable data regarding rates of candidaemia in neonatal ICUs could 
not be found, although Govender et al.[37] reported that a quarter 
of isolates collected in the TRAC-South Africa study were from 
neonates. If we assume that post-surgical Candida peritonitis is half 
as frequent as candidaemia in ICUs, as it was in France, then 1 807 
cases are anticipated. In 2015, 1 668 end-stage kidney disease patients 
received PD across SA.[13] In a Cape Town cohort of patients receiving 
PD in 2010, the incidence of peritonitis was 1.7 episodes per patient 
per year and 3.8% of episodes were caused by fungi.[42] In Limpopo, 
the incidence of PD-related peritonitis in 2008 was 0.8 episodes per 
year, also with 3.8% caused by fungi.[43] If we assume an average 
incidence of PD-related peritonitis of 1.3 episodes per patient per 
year, with 3.8% caused by Candida, then an additional 82 cases of 
Candida peritonitis are anticipated, for a total of 1 901 incident cases 
of Candida peritonitis (3.4 cases/100 000). We estimated 828  666 
PLWH with oral candidiasis, including 764 816 adults and 63 850 
children. Additionally, we estimated that 135 289 adult PLWH 
had oesophageal candidiasis. An estimated 1  002 499 women were 
afflicted by recurrent vulvovaginal candidiasis each year.
Several studies have reported on tinea capitis among children in sub-
Saharan Africa.[54] In 1976, Young[55] reported prevalence rates of tinea 
capitis of 19% and 12% among rural black children in the Northern 
Transvaal and Eastern Transvaal provinces of SA, respectively, with 
an overall prevalence of 15%. Using the conservative estimate that 6% 
of SA children aged <15 years would be affected by tinea capitis, we 
estimated 1  003 490 such infections. Among these, we estimate the 
occurrence of at least 20 000 and perhaps as many as 130 000 cases of 
inflammatory tinea capitis or kerion, a painful and stigmatising disease 
that can become complicated by permanent hair loss.[56,57]
Dimorphic fungal infections are reported sporadically and are 
occasionally associated with outbreaks. The recent introduction 
of molecular typing methods for identification of dimorphic fungi 
has resulted in recognition of Emergomyces africanus (formerly 
Emmonsia sp.) as the most common dimorphic fungus implicated 
in human disease in SA.[65] In a prospective study of PLWH with 
CD4+ counts <100 cells/µL and recent-onset, widespread skin 
lesions (the most common clinical manifestation of disease) who 
were receiving care at public sector hospitals in Cape Town, 14 cases 
of emergomycosis were diagnosed in as many months.[58] Among 
hospitals in Gauteng Province, 10 cases were diagnosed during a 
14-month period in 2014 - 2015 at Chris Hani Baragwanath Hospital 
alone.[66] In Eastern Cape Province, 5 cases were diagnosed in private 
sector hospitals between 2008 and 2013, but none in public sector 
hospitals.[67] Assuming that the ratio of public to private sector cases 
in the Eastern Cape is the same as in the Western Cape (10:1[67]), 
then an additional 45 public sector cases went undetected during this 
time. It is likely that many more cases are being misdiagnosed. We 
therefore estimated 100 cases of emergomycosis per year. Compared 
with emergomycosis, histoplasmosis appears to be less common in 
the Western Cape[58] and more common in KwaZulu-Natal.[68] Rarely, 
outbreaks associated with caving activities have been reported.[69,70] We 
889       November 2019, Vol. 109, No. 11
RESEARCH
estimated the occurrence of 60 cases per year. While blastomycosis 
is endemic to SA, it is uncommon;[71-74] we estimated 10 cases per 
year. Sporotrichosis, an implantation mycosis that can also present 
with pulmonary and disseminated disease in HIV,[58,75] has been 
implicated in sporadic infections and outbreaks in SA, the latter 
primarily reported among mineworkers.[59,76,77] We estimated 40 cases 
of sporotrichosis per year. We respectively estimated 40 cases and 
10  cases annually of chromoblastomycosis and eumycetoma, two 
other implantation mycoses.
A single study of infectious keratitis in Mopani District found 1 
of 46 (2.2%) cases to be fungal in aetiology using the less sensitive 
technique of corneal swabs; a country estimate of fungal keratitis 
caseload is not possible from these scanty data.[78]
Discussion
SA faces a number of important healthcare challenges, most notably 
HIV and associated infections including TB, but also antimicrobial-
resistant bacterial infections, food-borne outbreaks and non-
communicable diseases. Understanding the magnitude of respective 
problems will be critical for prioritising limited resources, but few 
national data are available to quantify the burden of fungal diseases in 
SA. The current study represents an attempt to estimate the burden of 
these infections, and adds to a growing number of national estimates 
demonstrating the substantial impact of mycoses.[4] We estimated 
an annual burden of ~3.2 million cases of fungal diseases in SA 
(excluding dermatophytes other than tinea capitis), suggesting that 
these infections cause significant morbidity in this country.
The most frequently encountered diseases, tinea capitis and 
recurrent vulvovaginal candidiasis, while not life-threatening, are 
stigmatising and potentially debilitating for those affected. Our 
estimate of just over 1 million women with recurrent vulvovaginal 
candidiasis differs slightly from figures reported for SA in a recent 
global estimate only because of differences in the source data for 
population estimates; underlying assumptions about the prevalence 
of recurrent vulvovaginitis on which the estimates were made 
are similar.[79] We were unable to quantify the incidence of fungal 
keratitis, a sight-threatening disease.
Some of the fungal diseases discussed here can be difficult to 
diagnose and are associated with high case-fatality rates. Cryptococcal 
meningitis is the leading cause of HIV-associated meningitis in 
southern Africa,[80-82] and a leading cause of death among PLWH. We 
estimated the occurrence of 8 357 cases of cryptococcal meningitis 
per year in SA. GERMS-SA identified 6 964 cases of laboratory-
confirmed cryptococcosis (excluding cryptococcal antigenaemia),[14] 
and we inflated this figure by 20% to account for additional cases that 
we presume have occurred in patients not receiving care or in whom 
the diagnosis was missed. This figure is considerably lower than that 
proposed by Rajasingham et al.,[83] who estimated the occurrence of 
21 400 cases of HIV-associated cryptococcal meningitis annually in 
SA. Our estimate may have been conservative, but it is based on the 
assumptions that untreated cryptococcal meningitis is uniformly 
fatal, that few individuals would die at home without presenting to 
hospital, and that only few patients with the disease who present in 
extremis would not be appropriately investigated by lumbar puncture. 
The case fatality rate of a first episode of cryptococcal disease in SA 
patients was reported to be 37%.[14] Fortunately, roll-out of serum 
cryptococcal antigen testing among persons with advanced HIV, 
led by the National Institute for Communicable Diseases (NICD), 
has enabled the detection and treatment of subclinical disease prior 
to progression to cryptococcal meningitis. A national programme 
implementing reflexive serum cryptococcal antigen screening of all 
HIV-seropositive patients with a CD4+ count <100 cells/µL achieved 
95% coverage (276 125 patients) in the first year, with cryptococcal 
antigenaemia detected in 15 757 patients (5.7%).[84]
Table 3. Estimated burden of fungal diseases in South Africa
Mycosis Rate, /100 000* Cases per year, n* Sensitivity bounds (lower - upper)
Cryptococcal meningitis 14.8 8 357 6 268 - 10 446
PCP 7.9 4 452 3 339 - 5 565
Invasive aspergillosis 4.8 3 885 2 914 - 4 856
CPA 158.2 89 416 67 062 - 111 770
ABPA 109.6 61 938 46 454 - 77 423
SAFS 131.5 74 326 55 745 - 92 908
Candidaemia 9.6 5 421 4 066 - 6 776
Peritoneal candidiasis 3.4 1 901 1 426 - 2 376
Oral candidiasis 1 466 828 666 621 500 - 1 035 833
Oesophageal candidiasis 239 135 289 101 467 - 169 111
Recurrent vulvovaginal candidiasis† 3 547 1 002 499 751 875 - 1 253 124
Tinea capitis 1 775 1 003 490 752 618 - 1 254 363
Mucormycosis 0.2 113 85 - 141
Emergomycosis 0.2 100 75 - 125
Histoplasmosis 0.1 60 45 - 75
Sporotrichosis 0.07 40 30 - 50
Blastomycosis 0.02 10 8 - 13
Chromoblastomycosis 0.07 40 30 - 50
Eumycetoma 0.02 10 8 - 13
Total 5.7 3 220 014 2 415 010 - 4 025 017 
*Rates are presented as cases per 100 000 to enable comparison across countries; however, rates for mycoses largely depend on the underlying condition or demographics, as detailed in the text 
and in Table 2. Cases are number of people affected in a given year. For some conditions (e.g. CPA, ABPA, SAFS, recurrent vulvovaginal candidiasis and eumycetoma) infections are chronic, and 
the rate therefore reflects prevalence. For all others, rate reflects incidence.
†Females only.
PCP = Pneumocystis pneumonia; CPA = chronic pulmonary aspergillosis; ABPA = allergic bronchopulmonary aspergillosis; SAFS = severe asthma with fungal sensitisation.
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The majority of studies that have described the incidence of PCP 
in sub-Saharan Africa have focused on specific populations of ill 
patients,[85] making determination of the true incidence challenging. 
We estimated 4 452 cases of PCP per year, including 1 691 cases in 
adults and 2 761 in children. Our estimate of the burden of PCP 
in children required an estimate of the proportion of childhood 
pneumonias caused by PCP; the most relevant study that we could 
find was from Botswana prior to the widespread use of ART,[17] 
and this may have led to an overestimation. It should also be noted 
that the number of cases proven by microscopy or by molecular 
testing is anticipated to be considerably fewer than our estimate, 
given limitations in the availability and the sensitivity of microscopy 
diagnosis.[86,87] For example, Chiliza et al.[87] reported that among 
adult PLWH hospitalised with suspected PCP at a tertiary hospital in 
Cape Town, the diagnosis was confirmed in just 55%.
We estimated 5 421 episodes of candidaemia in adults each year. 
A limitation of our estimate is that it extrapolates from data reported 
for a single large referral hospital’s ICU, which may not reflect the 
true incidence across the country. For comparison with available 
surveillance data, the NICD’s TRAC-South Africa passive laboratory-
based surveillance programme – which included just 11 public sector 
hospitals and 85 private sector hospitals – reported 2 172 cases of 
candidaemia over a 19-month period in 2009 and 2010.[37] However, 
there are at least 544 hospitals in SA,[88] suggesting that our estimate 
is reasonable. In the TRAC-South Africa surveillance, approximately 
a quarter of isolates were from neonatal ICUs,[89] and these were 
not incorporated into our estimates. Whereas C. albicans is the 
predominant Candida species involved in candidaemia in most parts 
of the world,[90] C. parapsilosis is the species most commonly implicated 
in candidaemia in SA, and many isolates are resistant to azole anti-
fungals.[37] The relatively high rate of C. parapsilosis is symptomatic 
of poor infection control procedures and/or limited antimicrobial 
stewardship, which may be important opportunities to reduce the 
burden of candidaemia and invasive candidiasis. Another major public 
health concern is the emergence and spread of C. auris, a multidrug-
resistant yeast associated with nosocomial transmission, which is 
increasingly being encountered in SA, particularly in ICUs in private 
sector hospitals.[91,92] Publication of empirical data collected through 
GERMS-SA is anticipated to clarify the true incidence of candidaemia 
in SA (N Govender, NICD, personal communication, December 2018).
We estimated 3 885 cases of IA complicating immunocompromi-
sing conditions or lung disease based on adjusted data extrapolated 
from resource-rich settings. In practice, few cases of IA are diagnosed 
in SA. The diagnosis of IA can be difficult, and usually relies on 
bronchoscopy for culture and/or galactomannan; the latter can 
also be used on serum. In SA, galactomannan testing is not widely 
available. Moreover, access to bronchoscopy is frequently limited to 
tertiary hospitals. Some international reports have found high rates of 
IA on autopsy of patients dying of HIV; for example, in Italy, Antinori 
et al.[24] diagnosed aspergillosis on 4% of postmortem examinations 
of such patients. However, autopsy studies of HIV-infected patients 
from SA have not reported this finding.[25-29]
The high number of cases of CPA in SA reflects the high burden of 
TB, and clearly requires validation. Unfortunately, the key laboratory 
diagnostic test (Aspergillus IgG antibody)[93] is not available in 
the country, despite its first being described in the 1960s and the 
development of multiple commercial assays since then.[94,95] With a 
50 - 80% 5-year mortality, this diagnostic gap is important to address 
nationally.
ABPA and SAFS, collectively known as ‘fungal asthma’, are also 
relatively common: asthma in adults has been measured at 6%.[10] 
The estimate of ABPA is based on SA data from 1980 in a referral 
population of asthmatics.[34] Referral patterns could affect this figure, 
and there may have been changes over the intervening 38 years. 
Fungal sensitisation studies are rare in Africa, and in SA limited to 
sensitivity of infants to Alternaria spp.,[96] limiting the reliability of 
our estimate of the burden of SAFS. Clearly, with >100 000 adults 
affected (and an unknown number of children), fungal asthma needs 
to be addressed in SA as it is amenable to antifungal therapy as well 
as the usual treatments for asthma.[36]
HIV-associated endemic fungal infections such as emergomycosis, 
histoplasmosis and sometimes sporotrichosis are frequently 
misdiagnosed, and diagnostic delays are commonly fatal.[58,67] 
Blastomycosis, which is not typically associated with HIV, is frequently 
characterised by a protracted course and is commonly misdiagnosed – 
especially as TB; deaths have been infrequently reported.[63] These and 
other fungal diseases are not notifiable in SA,[97] so the true incidences 
are unclear.
Similar attempts have been made to estimate the burden of fungal 
disease for other countries in sub-Saharan Africa[98-101] and elsewhere.[4] 
Compared with other countries, SA has high burdens of HIV-associated 
and TB-associated fungal infections, reflecting the disproportionate 
size of these dual public health scourges. The proportion of patients 
affected by CPA is probably the largest in the world at 175.8/100 000. In 
comparison, TB-associated CPA rates were estimated for both Nigeria 
and the Democratic Republic of the Congo as 42.9/100 000 in 2011,[32] 
and more recently for India as 24/100  000. [102] Rajasingham et al.[83] 
estimated the incidence of cryptococcal meningitis across countries 
with a uniform methodology, and found the largest burden in SA, 
reflecting the scale of HIV in this country.[83]
Our objective is for the estimates presented here to fill knowledge 
gaps regarding the burden of fungal disease in SA, pending the 
availability of empirical data. Robust epidemiological studies with 
optimal diagnostics are required to clarify the true incidence and 
prevalence of fungal infections. Importantly, the NICD is currently 
conducting critical surveillance for some of these infections (including 
candidaemia and cryptococcal meningitis through GERMS-SA), 
which will be important for supporting or supplanting some of our 
estimates. Additionally, careful repeated data collection over years will 
be important to establish trends, which we have not attempted here.
Many improvements in diagnostics could transform both the 
quality of current epidemiological data on fungal diseases in SA and 
patient care. The absence (or near absence) of Aspergillus antigen 
(galactomannan), Aspergillus IgG, Aspergillus IgE, and Histoplasma 
antigen and antibody testing are the most important gaps. Even 
direct microscopy for fungi is not available in most hospitals. The 
quiet revolution and incremental improvements in fungal disease 
diagnostics over the past two decades have almost bypassed SA, with 
the one important exception of cryptococcal antigen testing in HIV 
patients, in which SA is leading the world in terms of screening and 
case finding. Fortunately, most of the newest and best fungal diagnostic 
tests are inexpensive (<USD10), and given their critical importance 
to high-quality care, they should be implemented across the country. 
In addition, access to effective therapy remains a challenge for many 
patients. Perhaps foremost among the medications to which access is 
urgently needed is flucytosine, an over-50-year-old medicine shown 
to reduce mortality from cryptococcal meningitis compared with 
alternatives, but which remains inaccessible in SA.[103,104]
Conclusions
Fungal infections cause a high burden of disease in SA and should 
be considered an important public health concern. The majority of 
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these diseases are complications of HIV, TB, and/or poverty. While 
public health investment in the underlying conditions is essential, 
improving strategies for the prevention, diagnosis and management 
of fungal diseases can help address the morbidity and mortality 
associated with these conditions.[105]
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